Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setrusumab Phase 2/3 study in osteogenesis imperfecta
NL-OMON53714Phase 3Recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteogenesis imperfecta (OI) comparing Setrusumab with Placebo (2 arms). Primary endpoints: Phase 2 primary endpoint and Phase 3 primary endpoint. Started Nov 2023; status: recruiting.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NL-OMON53714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53714.